Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of glasdegib added to intensive or non‑intensive chemotherapy in untreated AML
jRCT2080223841Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of glasdegib in acute myeloid leukemia (AML) (4 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Mar 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223841.